Company intelligence / Profile preview
Praetego
- Ownership
- Private
- Development stage
- Preclinical
Overview
Praetego’s lead candidate PTG‑630 has demonstrated neuroprotection in preclinical models of AD and DPN, showing protection against mild cognitive impairment and biomarker evidence of neuronal benefit. IND-enabling studies are ongoing with an IND filing planned for late 2024. The company has received multiple NIH grants to advance its programs toward clinical trials.
A Phase 2 study will target diabetics with mild cognitive impairment at high risk for AD to demonstrate target engagement and proof of mechanism.
Additional preclinical work supports expansion into diabetic retinopathy as a third indication.
No human clinical results reported yet.- Therapeutic areas
- OphthalmologyEndocrinologyNeurology
- Modalities
- Small molecules (Amadorins)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Praetego.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Praetego.